MF59™ as a vaccine adjuvant: a review of safety and immunogenicity (Q30394545)

21 June 2017

MF59™ as a vaccine adjuvant: a review of safety and immunogenicity (English)

1 reference

21 June 2017

Hana El Sahly

1

1 reference

21 June 2017

1 October 2010

1 reference

Expert Review of Vaccines

21 June 2017

1 reference

21 June 2017

9

1 reference

21 June 2017

1135-1141

1 reference

21 June 2017

10

1 reference

NEW METABOLIZABLE IMMUNOLOGIC ADJUVANT FOR HUMAN USE. 3. EFFICACY AND TOXICITY STUDIES IN MAN.

21 June 2017

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

New metabolizable immunologic adjuvant for human use. 5. Evaluation of highly purified influenza-virus vaccine in adjuvant 65.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

Enhancement of antibody responses to influenza B virus haemagglutinin by use of a new adjuvant formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

Sterol, Structure and Membrane Function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

Dendritic cells internalize vaccine adjuvant after intramuscular injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

Molecular and cellular signatures of human vaccine adjuvants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

Advances in vaccine adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

Evidence of bias in estimates of influenza vaccine effectiveness in seniors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

Modulation of the immune response to the severe acute respiratory syndrome spike glycoprotein by gene-based and inactivated virus immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

A universal vaccine for serogroup B meningococcus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

Adjuvant can improve protection induced by OMV vaccine against Neisseria meningitidis serogroups B/C in neonatal mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

Immunization with the Chlamydia trachomatis major outer membrane protein, using adjuvants developed for human vaccines, can induce partial protection in a mouse model against a genital challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

Intranasal immunization with recombinant gD2 reduces disease severity and mortality following genital challenge with herpes simplex virus type 2 in guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

A comparison of biodegradable microparticles and MF59 as systemic adjuvants for recombinant gD from HSV-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

Intranasal immunization of mice with herpes simplex virus type 2 recombinant gD2: the effect of adjuvants on mucosal and serum antibody responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

21 January 2018

Safety of MF59 adjuvant

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

Exposure to MF59-adjuvanted influenza vaccines during pregnancy--a retrospective analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

Adjuvants and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

Antibodies to squalene in Gulf War syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

Re: Antibodies to squalene in Gulf War Syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

Detection of antibodies to squalene: III. Naturally occurring antibodies to squalene in humans and mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

Vaccine prevention of maternal cytomegalovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

Antigenicity of Soluble Protein in the Presence of High Levels of Antibody : a Possible Mode of Action of the Antigen Adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.111

21 January 2018

Identifiers

DOI

10.1586/ERV.10.111

1 reference

21 June 2017

1 reference

PubMed ID

20923265